Literature DB >> 71600

Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure.

S A Atlas, J E Sealey, J H Laragh, C Moon.   

Abstract

An inactive form of renin is activated by incubating human plasma at -5 degrees C. The relative proportions of active renin and this cryoactivatable "prorenin" in plasmas of untreated hypertensive patients varied widely. However, prorenin increased in parallel with active renin after sodium deprivation or diuretic therapy in 36 patients; the increases were similar whether or not blood-pressure fell. In contrast, propranolol administration in 22 patients lowered active renin in all, but it increased prorenin by 98% in 15 in whom systolic pressure fell. In the other 7 blood-pressure did not change, and beta-blockade produced a fall in total renin (active renin plus prorenin) while prorenin was unchanged. For all 22 there was an inverse relationship between propranolol-induced changes in plasma-prorenin and systolic pressure (r=-0-77, P less than 0-001). The fraction of active plasma-renin fell during propranolol administration from 43% to 18%, regardless of the blood-pressure response. Clonidine produced similar changes in 10 patients. Thus, sodium depletion stimulates total renin release, while propranolol and clonidine produce divergent responses of active renin and prorenin, the changes in prorenin depending on the changes induced in blood-pressure. These observations suggest that propranolol may block intrarenal conversion of prorenin to active renin while also suppressing total renin release. But the latter effect may be offset by concurrent baroreceptor-mediated release of total renin (mostly prorenin) when blood-pressure is lowered.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71600     DOI: 10.1016/s0140-6736(77)90723-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Active and inactive renin after exercise.

Authors:  M Ikeda; M Matsusaki; A Kinoshita; M Koga; M Ideishi; M Sasaguri; H Tanaka; M Shindo; K Arakawa
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

Review 2.  Ovarian hyperstimulation syndrome: a review of pathophysiology.

Authors:  P A Bergh; D Navot
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

3.  Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms.

Authors:  M L Tuck; M S Golub; P Eggena; J R Sowers; M Maxwell
Journal:  West J Med       Date:  1983-08

4.  Cyclical secretion of prorenin during the menstrual cycle: synchronization with luteinizing hormone and progesterone.

Authors:  J E Sealey; S A Atlas; N Glorioso; H Manapat; J H Laragh
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise.

Authors:  P J Lijnen; A K Amery; R H Fagard; T M Reybrouck; E J Moerman; A F De Schaepdryver
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

6.  The renin/angiotensin system.

Authors:  M R Lee
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

7.  Acid- and cryoactivation of renin in human plasma.

Authors:  W Hummerich; A Konrads; M Schrappe; A Helber; G Wambach
Journal:  Klin Wochenschr       Date:  1979-05-03

8.  Renal beta-adrenoceptors in thyroxine-treated rats.

Authors:  J M Haro; J M Sabio; F Vargas
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

9.  Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.

Authors:  Kamel A Gharaibeh; Stephen T Turner; Abdurrahman M Hamadah; Arlene B Chapman; Rhonda M Cooper-Dehoff; Julie A Johnson; John G Gums; Kent R Bailey; Gary L Schwartz
Journal:  Am J Hypertens       Date:  2016-06-30       Impact factor: 2.689

10.  Effect of metoprolol on 24-hour urinary excretion of adrenal steroids and kallikrein in patients with essential hypertension.

Authors:  E Fritschka; R Gotzen; R Kittler; M Schöneshöfer
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.